Obesity Clinical Trial
Official title:
PATH to Health: An Exploration of Digital Behavioral Weight Loss Approaches
NCT number | NCT05929469 |
Other study ID # | 23-0396 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2, 2023 |
Est. completion date | April 25, 2024 |
Verified date | October 2023 |
Source | University of North Carolina, Chapel Hill |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this initial pilot and feasibility study is to test different digital, behavioral weight loss approaches, with or without human support, using a sequential, multiple assignment, randomized trial (SMART) design. All participants in this pilot trial will receive a 3-month mobile health (mHealth) program. The dose of human support will vary by first- and second-line randomizations. The feasibility, acceptability, and preliminary outcomes for each of the treatment sequences will be assessed.
Status | Completed |
Enrollment | 99 |
Est. completion date | April 25, 2024 |
Est. primary completion date | April 25, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Current age: 18-65 years - Lives in North Carolina - Body mass index (BMI) of 27.5-45 kg/m^2 - Ability to read, write, and speak English - Ownership of iPhone with a data and texting plan - Ability to commit to the required counseling sessions (0-5 sessions, based on randomization) - Is not living a participant or staff member on this trial - Willingness to be randomized to any of the treatment sequences Exclusion Criteria: - Weight loss of more than 10 pounds in the last 6 months that was maintained - A history of weight loss surgery - Pre-existing medical condition(s) that prevent them from adhering to a supervised exercise routine - Have Type 1 Diabetes or are currently taking medicine for Type 2 Diabetes - Have recently been diagnosed or treated for cancer - Currently pregnant, pregnant within the past 6 months, or plan to become pregnant in the next 6 months - Report taking prescription or over the counter medication with a known impact on metabolism or weight - Report a history of an eating disorder - History of psychotic disorder or bipolar disorder, or have been hospitalized for depression or other psychiatric disorder within the past 12 months - History of alcohol or substance abuse - Current participation in another weight loss program that may interfere with participation in this study |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
University of North Carolina, Chapel Hill | Academy of Nutrition and Dietetics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility- Rate of early nonresponse | The rate of early response will be calculated as the number of individuals deemed "early responders" divided by the total number of participants randomized. | 4 weeks | |
Primary | Feasibility- Percentage of participants with missing data at 4 weeks | The percentage of participants with missing data at 4 weeks will be calculated as the number of participants who do not complete the 4-week weight assessment divided by the total number of participants randomized. | 4 weeks | |
Secondary | Weight Change- Percent weight change from baseline to 3 months | Percent weight change from baseline to 3 months will be calculated ((3 month weight - baseline weight)/100). Weight will be objectively measured on a scale in the participant's home. | Baseline, 3 months | |
Secondary | Weight Change- Percent weight change from baseline to 4 weeks | Percent weight change from baseline to 4 weeks will be calculated ((4 week weight - baseline weight)/100). Weight will be objectively measured on a scale in the participant's home | Baseline, 4 weeks | |
Secondary | Weight Change- Percent weight change from 4 weeks to 3 months | Percent weight change from 4 weeks to 3 months will be calculated ((3 month weight - 4 week weight)/100). Weight will be objectively measured on a scale in the participant's home | 4 weeks, 3 months | |
Secondary | Acceptability- Rate of attendance at human support sessions | The rate of attendance at human support sessions will be calculated as the number of human sessions completed divided by the number of human sessions assigned. | Up to 3 months | |
Secondary | Acceptability- Attrition | Attrition will be calculated as the number of intervention participants who did not complete 3-month weight measures divided by the number randomized to treatment. | Up to 3 months | |
Secondary | Acceptability- Overall program satisfaction rating | Overall program satisfaction will be assessed using a single item, which asks participants to rate their overall satisfaction with the program on a 4-point Likert scale that ranges from "very dissatisfied" to "very satisfied," in which higher scores indicate greater levels of satisfaction. | 3 months | |
Secondary | Weighing Self-Monitoring Adherence | Number of days of self-weighing over the 3 month period, measured by use of the scale in the participant's home. | Baseline to 3 months (daily) | |
Secondary | Dietary Self-Monitoring Adherence | Number of days of complete dietary tracking summed over the 3-month study period, as measured by app use data. | Baseline to 3 months (daily) | |
Secondary | Physical Activity Self-Monitoring Adherence | Number of days of physical activity tracking over the 3 month period, as measured by Fitbit tracker wear. | Baseline to 3 months (daily) | |
Secondary | Dietary Goal Adherence | Number of days the participant met their daily calorie goal over the 3 month period, as measured by app data. | Baseline to 3 months (daily) | |
Secondary | Activity Goal Adherence | Number of days the participant met their active minutes goal over the 3 month period, as measured by app data. | Baseline to 3 months (daily) | |
Secondary | Change in Diet | Change in daily caloric intake from baseline to 3 months, as measured using the self- administered National Cancer Institute's Automated Self- Administered 24-hour Recall (ASA-24), a 24-hour recall that is self-administered on one day at each timepoint. | Baseline, 3 months | |
Secondary | Change in Physical Activity | Change in physical activity from baseline to 3 months, as measured using the Paffenbarger Physical Activity Questionnaire (PPAQ). The PPAQ assesses amount of planned and lifestyle associated physical activity performed during a typical week. The PPAQ consists of three components: (1) stair climbing, (2) walking, and (3) sports and recreation. Participants report the frequency and duration of physical activity in the past week. Scoring yields energy expenditure from physical activity per week (kcal/kg/week). Higher scores translate into greater energy expenditure per week (i.e.,better outcome). Range is 0 - no theoretical maximum. | Baseline, 3 months | |
Secondary | Change in Motivation | Change in motivation from baseline to 4 weeks and 3 months, as measured using the Treatment Self-Regulation Questionnaire (TSRQ). The TSRQ assesses autonomous and controlled motivation for weight management. Six items assess autonomous motivation and six assess controlled motivation using a 7 point Likert scale, in which 1 corresponds to "not at all true" and 7 corresponds to "very true." Items will be averaged to produce scores for autonomous motivation and controlled motivation ranging from 1-7. Higher values on each sub-scale indicate greater levels of that type of motivation. A Relative Autonomous Index (RAI) score will be separately calculated by subtracting the controlled motivation score from the autonomous motivation score. The range of possible RAI scores is -6 to 6. | Baseline, 1 week, 4 weeks, 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |